This registry is a prospective observational study in order to describe primarily the natural course of PP subtypes and to gain detailed information about their phenotype.
This project is to describe the natural course of disease in different subtypes of PP. The network builds on a static registry that was based on a one-time clinical characterization of PP patients in Europe (ERASPEN). The International Rare and Severe Psoriasis Expert Network (IRASPEN) already has multiple clinicians involved who have successfully characterized and included their patients in ERASPEN. IRASPEN addresses the question of temporal evolution of clinical features and is actually a non-interventional prospective registry that aims to describe the clinical course and responses to already established treatments of a large number of PP patients over a period of 5 years. The data collection with this registry will give insight on the natural course of PP disease revealing the burden of disease including frequency and severity of flares and the role of therapeutic interventions.
Study Type
OBSERVATIONAL
Enrollment
180
In order to investigate the level of molecular pathophysiology, blood and punch biopsies will be collected of each patient. In up to two relatives per patient, 30mL blood will be collected only once.
Phenotypic characterization of the patient's clinical features
All affected areas will be photographed at each visit with 2-dimensional standardized photography
Klinikum der Universität München
München, Germany
RECRUITINGFondazione Policlinico Universitario "Agostino Gemelli" IRCCS
Rome, Italy
RECRUITINGUniversitário do Porto
Porto, Portugal
Change in Physician Global Assessment (PGA)
modified PGA (physician's assessment of psoriatic lesions) scoring the erythema, pustules, and scaling of all GPP or PPP lesions from 0 to 4. Each component is graded separately, the average is calculated, and the final PGA is determined from this composite score. A lower score indicates a lesser severity, with 0 being clear and 1 being almost clear.
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in Generalized Pustular Psoriasis (GPP) Area and Severity Index (GPPASI)
Measure of severity and area of psoriatic lesions in patients with psoriasis. It is a tool that provides a numeric scoring for a patient's overall GPP disease state,ranging from 0 to 72. It is a linear combination of percent of surface area of skin that is affected by erythema, pustules and scaling and the severity of erythema, pustules, and scaling (desquamation) over 4 body regions.
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in Dermatology Life Quality Index (DLQI)
The Dermatology Life Quality Index (DLQI) consists of 10 questions concerning patient's perception of the impact of skin diseases on different aspects of their health related QoL over the last week. The DLQI evaluates the impact of the patient's skin disease on daily activities, leisure, work and personal relationships. Each question is scored on a 4-point Likert scale.
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in EuroQol (EQ-5D)
The EuroQol is a generic questionnaire. It is a preference based health status and multi attribute utility scale that produces a single index score for each state of health. These score ranges from 0 to 1, where 1 is equivalent to full health and 0 equivalent to death
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
National Skin Centre
Singapore, Singapore
RECRUITINGDermatology, University Hospital Basel
Basel, Switzerland
RECRUITINGUniversity Hospital Zürich
Zurich, Switzerland
RECRUITINGAkdeniz University School of Medicine; Department of Dermatology and Venereology
Antalya, Turkey (Türkiye)
RECRUITINGTrakya University, Faculty of Medicine; Department of Dermatology and Venereology
Edirne, Turkey (Türkiye)
RECRUITINGChange in Work Productivity and Activity Impairment Questionnaire-General Health (WPAI-GH)
The Work Productivity and Activity Impairment Questionnaire-General Health (WPAI-GH) consists of six questions: 1 = currently employed; 2 = hours missed due to health problems; 3 = hours missed other reasons; 4 = hours actually worked; 5 = degree health affected productivity while working (using a 0 to 10 Visual Analogue Scale (VAS)); 6 = degree health affected productivity in regular unpaid activities (VAS)\[
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in psoriasis symptom scale (PSS)
The psoriasis symptom scale (PSS) is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to assess how unpredictable, uncontrollable, and overloaded respondents find their lives to be. The scale also includes a number of direct queries about current levels of experienced stress. Moreover, the questions are of a general nature and hence are relatively free of content specific to any sub-population group. The questions in the PSS ask about feelings and thoughts during the last month.
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in Disease activity Visual analogue Scale (VAS)
The disease VAS is a unidimensional measure of disease intensity. The VAS is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. To avoid clustering of scores around a preferred numeric value, numbers or verbal descriptors at intermediate points are not given. The disease intensity VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their current disease intensity.
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in Pain Visual analogue Scale (VAS)
The pain VAS is a unidimensional measure of pain intensity, which has been widely used in diverse adult populations. The pain VAS is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme. To avoid clustering of scores around a preferred numeric value, numbers or verbal descriptors at intermediate points are not given. The pain VAS is self-completed by the respondent. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity.
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Number of flares in the last 2 years
Number of flares in the last 2 years
Time frame: at Baseline
Number of flares since the last visit
Number of flares since the last visit
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in Palmoplantar Pustulosis (PPP) Area and Severity Index (PPPASI)
investigator assessment of the extent and severity of pustular and plaque lesions on the palms and soles presenting in PPP patients. This tool provides a numeric scoring for patients overall PPP disease state, ranging from 0 to 72. It is a linear combination of the percent of surface area of skin that is affected on the palms and soles of the body and the severity of erythema, pustules, and scaling (desquamation).
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260
Change in Psoriasis Area and Severity Index (PASI)
The Psoriasis Area and Severity Index (PASI) is a composite variable used to assess the severity of Psoriasis. The PASI evaluates the area of psoriatic involvement in 4 main areas (head, trunk, upper and lower extremities) and the severity of the psoriatic lesions with respect to three target symptoms: erythema, infiltration and desquamation (actual percentages of area involvement) .
Time frame: At Baseline, week 12, week 24, week 52, week 104, week 156, week 208, week 260